LHX3 Interacts with Inhibitor of Histone Acetyltransferase Complex Subunits LANP and TAF-1β to Modulate Pituitary Gene Regulation

por Hunter, Chad S., Malik, Raleigh E., Witzmann, Frank A., Rhodes, Simon J.
Publicado 2013

Patient Perceptions of and Preferences Between Characteristics of Injectable Diabetes Treatments

por Boye, Kristina S., Jordan, Jessica B., Malik, Raleigh E., Currie, Brooke M., Matza, Louis S.
Publicado 2021

OR28-4 Efficacy and Safety of Tirzepatide Versus Semaglutide in a Hispanic or Latino Population: A Prespecified Subgroup Analysis of SURPASS-2

por Benneyworth, Brian D, Brown, Katelyn, Malik, Raleigh E, Wang, Hui, Frias, Juan P
Publicado 2022

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review

por Robinson, Susan, Boye, Kristina S., Mody, Reema, Strizek, Alena Antonie, Konig, Manige, Malik, Raleigh E., Kennedy-Martin, Tessa
Publicado 2020

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11

por Frias, Juan P., Bonora, Enzo, Cox, David A., Bethel, M. Angelyn, Kwan, Anita Y.M., Raha, Sohini, Malik, Raleigh E.
Publicado 2021

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11

por Bonora, Enzo, Frias, Juan P., Tinahones, Francisco J., Van, Joanna, Malik, Raleigh E., Yu, Zhuoxin, Mody, Reema, Bethel, Angelyn, Kwan, Anita Y. M., Cox, David A.
Publicado 2021